Return to Today's science sparks archives

Information Click the tweet icon above each article title to share it on Twitter.

2021-11-26

Fig 3. Spectrum of somatic alterations associated with response to immune-checkpoint blockade (ICB)

Fig 3. Spectrum of somatic alterations associated with response to immune-checkpoint blockade (ICB)
  • Attalla K, DiNatale RG, Rappold PM, Fong CJ, Sanchez-Vega F, Silagy AW, Weng S, Coleman J, Lee CH, Carlo MI, Durack JC, Solomon SB, Reuter VE, Russo P, Chan TA, Motzer RJ, Schultz ND, Reznik E, Voss MH, Hakimi AA

  • Clin Cancer Res. 2021 Oct 15;27(20):5595-5606. doi: 10.1158/1078-0432.CCR-20-4058. Epub 2021 Jul 14.

2021-11-24

Fig 1. A) Trainee reported experience (in numbers of cases) with the treatment of individual hematologic malignancies diagnoses and specialized radiation therapy techniques. B) Trainee reported comfort with various aspects of hematologic malignancies patient care

Fig 1. A) Trainee reported experience (in numbers of cases) with the treatment of individual hematologic malignancies diagnoses and specialized radiation therapy techniques. B) Trainee reported comfort with various aspects of hematologic malignancies patient care
  • Kahn JM, Yang JC, Yahalom J, Dabaja BS, Vapiwala N, Hoppe BS, Tseng YD, Pinnix CC, Parikh RR, Sim AJ, Plastaras JP, Gunther JR

  • J Cancer Educ. 2021 Oct 2. pii: 10.1007/s13187-021-02098-9. doi: 10.1007/s13187-021-02098-9.
Open Access button

2021-11-23

Fig. 5: Dispensability of germline pathogenicity in tumorigenesis.

Fig. 5: Dispensability of germline pathogenicity in tumorigenesis.
  • Srinivasan P, Bandlamudi C, Jonsson P, Kemel Y, Chavan SS, Richards AL, Penson AV, Bielski CM, Fong C, Syed A, Jayakumaran G, Prasad M, Hwee J, Sumer SO, de Bruijn I, Li X, Gao J, Schultz N, Cambria R, Galle J, Mukherjee S, Vijai J, Cadoo KA, Carlo MI, Walsh MF, Mandelker D, Ceyhan-Birsoy O, Shia J, Zehir A, Ladanyi M, Hyman DM, Zhang L, Offit K, Robson ME, Solit DB, Stadler ZK, Berger MF, Taylor BS

  • Nat Genet. 2021 Nov;53(11):1577-1585. doi: 10.1038/s41588-021-00949-1. Epub 2021 Nov 5.

2021-11-22

Visual Abstract.

Visual Abstract.
  • Imber BS, Chau KW, Lee J, Lee J, Casey DL, Yang JC, Wijentunga NA, Shepherd A, Hajj C, Qi S, Chelius MR, Hamlin PA, Palomba ML, Joffe E, Zhang Z, Zelenetz AD, Salles GA, Yahalom J

  • Blood Adv. 2021 Oct 26;5(20):4185-4197. doi: 10.1182/bloodadvances.2021004939.
Open Access button

2021-11-19

Graphical Abstract.

Graphical Abstract.
  • Chan JM, Quintanal-Villalonga A, Gao VR, Xie Y, Allaj V, Chaudhary O, Masilionis I, Egger J, Chow A, Walle T, Mattar M, Yarlagadda DVK, Wang JL, Uddin F, Offin M, Ciampricotti M, Qeriqi B, Bahr A, de Stanchina E, Bhanot UK, Lai WV, Bott MJ, Jones DR, Ruiz A, Baine MK, Li Y, Rekhtman N, Poirier JT, Nawy T, Sen T, Mazutis L, Hollmann TJ, Pe'er D, Rudin CM

  • Cancer Cell. 2021 Nov 8;39(11):1479-1496.e18. doi: 10.1016/j.ccell.2021.09.008. Epub 2021 Oct 14.
Open Access button

2021-11-18

Fig. 3: The tumor–microenvironment interface is composed of specialized tumor and muscle cells.

Fig. 3: The tumor–microenvironment interface is composed of specialized tumor and muscle cells.
  • Hunter MV, Moncada R, Weiss JM, Yanai I, White RM

  • Nat Commun. 2021 Nov 1;12(1):6278. doi: 10.1038/s41467-021-26614-z.
Open Access button

2021-11-17

Fig. 6. Sankey diagram shows management decisions before (left) and after (right) 18F-FDG-PET and PET/CT in patients with cancer of unknown primary.

Fig. 6. Sankey diagram shows management decisions before (left) and after (right) 18F-FDG-PET and PET/CT in patients with cancer of unknown primary.
  • Woo S, Becker AS, Do RKG, Schoder H, Hricak H, Alberto Vargas H

  • Eur J Cancer. 2021 Nov 2;159:60-77. doi: 10.1016/j.ejca.2021.09.031.

2021-11-16

Graphical Abstract

Graphical Abstract
  • Kruse ML, Patel M, McManus J, Chung YM, Li X, Wei W, Bazeley PS, Nakamura F, Hardaway A, Downs E, Chandarlapaty S, Thomas M, Moore HC, Budd GT, Tang WHW, Hazen SL, Bernstein A, Nik-Zainal S, Abraham J, Sharifi N

  • JCI Insight. 2021 Oct 22;6(20). pii: e150403. doi: 10.1172/jci.insight.150403.
Open Access button

2021-11-15

Figure 2. Timeline of Important Dates.

Figure 2. Timeline of Important Dates.
  • Wijetunga NA, Imber BS, Caravelli JF, Mikhaeel NG, Yahalom J

  • Br J Radiol. 2021 Nov 1;94(1127):20210285. doi: 10.1259/bjr.20210285. Epub 2021 Jul 8.

2021-11-12

Figure 3. Patient assessment of the telemedicine on-treatment management visit.

Figure 3. Patient assessment of the telemedicine on-treatment management visit.
  • Shaverdian N, Gillespie EF, Cha E, Kim SY, Benvengo S, Chino F, Kang JJ, Li Y, Atkinson TM, Lee N, Washington CM, Cahlon O, Gomez DR

  • J Natl Compr Canc Netw. 2021 Jan 4:1-7. doi: 10.6004/jnccn.2020.7687.
Open Access button

2021-11-11

Fig. 3: Mitochondrial GSH import is essential for cell proliferation.

Fig. 3: Mitochondrial GSH import is essential for cell proliferation.
  • Wang Y, Yen FS, Zhu XG, Timson RC, Weber R, Xing C, Liu Y, Allwein B, Luo H, Yeh HW, Heissel S, Unlu G, Gamazon ER, Kharas MG, Hite R, Birsoy K

  • Nature. 2021 Nov;599(7883):136-140. doi: 10.1038/s41586-021-04025-w. Epub 2021 Oct 27.
Open Access button

2021-11-10

Abstract.

Abstract.
  • Ginsberg SD, Joshi S, Sharma S, Guzman G, Wang T, Arancio O, Chiosis G

  • J Neurochem. 2021 Oct 17. doi: 10.1111/jnc.15525.
Open Access button

2021-11-09

Figure 3 Overall survival and progression-free survival in resected patients (A) and unresected patients (B).

Figure 3 Overall survival and progression-free survival in resected patients (A) and unresected patients (B).
  • McIntyre CA, Cohen NA, Goldman DA, Gonen M, Sadot E, O'Reilly EM, Varghese AM, Yu KH, Balachandran VP, Soares KC, D'Angelica MI, Drebin JA, Kingham TP, Allen PJ, Wei AC, Jarnagin WR

  • J Surg Oncol. 2021 Oct 31. doi: 10.1002/jso.26735.

2021-11-08

Graphical Abstract

Graphical Abstract
  • Hirschhorn D, Betof Warner A, Maniyar R, Chow A, Mangarin LM, Cohen AD, Hamadene L, Rizzuto GA, Budhu S, Suek N, Liu C, Houghton AN, Merghoub T, Wolchok JD

  • JCI Insight. 2021 Oct 22;6(20). pii: 151035. doi: 10.1172/jci.insight.151035.
Open Access button

2021-11-05

Fig. 1: Genomic landscape of RAD51B-associated cancers.

Fig. 1: Genomic landscape of RAD51B-associated cancers.
  • Setton J, Selenica P, Mukherjee S, Shah R, Pecorari I, McMillan B, Pei IX, Kemel Y, Ceyhan-Birsoy O, Sheehan M, Tkachuk K, Brown DN, Zhang L, Cadoo K, Powell S, Weigelt B, Robson M, Riaz N, Offit K, Reis-Filho JS, Mandelker D

  • NPJ Breast Cancer. 2021 Oct 11;7(1):135. doi: 10.1038/s41523-021-00339-0.
Open Access button

2021-11-04

Figure 3. TAM and T cell phenotypes associated with response to optimized therapy regimen.

Figure 3. TAM and T cell phenotypes associated with response to optimized therapy regimen.
  • Wang Y, Liu S, Yang Z, Algazi AP, Lomeli SH, Wang Y, Othus M, Hong A, Wang X, Randolph CE, Jones AM, Bosenberg MW, Byrum SD, Tackett AJ, Lopez H, Yates C, Solit DB, Ribas A, Piva M, Moriceau G, Lo RS

  • Cancer Cell. 2021 Oct 11;39(10):1375-1387.e6. doi: 10.1016/j.ccell.2021.07.023. Epub 2021 Aug 19.
Open Access button

2021-11-03

Fig 1. Model of metabolic regulation of tumor immunogenicity: oncogenic-driven metabolic rewiring required for cancer cell growth can promote tumor immunogenicity.

Fig 1. Model of metabolic regulation of tumor immunogenicity: oncogenic-driven metabolic rewiring required for cancer cell growth can promote tumor immunogenicity.
  • Somarribas Patterson LF, Vardhana SA

  • Trends Immunol. 2021 Oct 2. pii: S1471-4906(21)00178-2. doi: 10.1016/j.it.2021.09.002.

2021-11-02

Fig. 1: Immune cell atlas of the LR-CHL microenvironment at single-cell resolution.

Fig. 1: Immune cell atlas of the LR-CHL microenvironment at single-cell resolution.
  • Aoki T, Chong LC, Takata K, Milne K, Marshall A, Chavez EA, Miyata-Takata T, Ben-Neriah S, Unrau D, Telenius A, Boyle M, Weng AP, Savage KJ, Scott DW, Farinha P, Shah SP, Nelson BH, Steidl C

  • Proc Natl Acad Sci U S A. 2021 Oct 12;118(41). pii: 2105822118. doi: 10.1073/pnas.2105822118.
Open Access button

2021-11-01

Fig. 1. Maximal response to therapy by mutation status in patients with NSCLC.

Fig. 1. Maximal response to therapy by mutation status in patients with NSCLC.
  • Gutierrez M, Guo R, Giaccone G, Liu SV, Hao Z, Hilton C, Hinson JM Jr, Kris MG, Orlemans EO, Drilon A

  • Lung Cancer. 2021 Oct 8;162:23-28. doi: 10.1016/j.lungcan.2021.10.001.